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Abstract
Background: In clinical practice, temporary interruption of rheumatoid arthritis (RA) therapy is common for various
reasons including side effects, non-compliance, or necessity for surgery. To characterize temporary interruptions of
baricitinib and placebo-matched tablets in phase 3 studies of patients with moderate-to-severe rheumatoid arthritis
(RA) and describe their impact on efficacy and safety.
Methods: During 4 baricitinib phase 3 studies, investigators documented timing, reason, and duration of
investigator-initiated temporary interruptions of study drug. In 2 studies, patients recorded RA symptoms in daily
diaries for 12 weeks. Post hoc analyses investigated changes in symptom scores during interruptions and
resumption of treatment. Interruptions were evaluated for reoccurrence of adverse events or laboratory
abnormalities after retreatment.
Results: Across the placebo-controlled studies, interruptions occurred in larger proportions of baricitinib- (2 mg,
18%; 4 mg, 18%) vs placebo-treated (9%) patients in only one study (bDMARD-inadequate responder patients, RA-
BEACON). In the active comparator-controlled studies, the lowest rates of interruption were in the baricitinib
monotherapy arm (9%) of RA-BEGIN (vs methotrexate monotherapy or combination therapy), and proportions were
similar for baricitinib (10%) and adalimumab (9%) in RA-BEAM. Adverse events were the most common reason for
interruption, but their reoccurrence after drug restart was infrequent. Most interruptions lasted ≤ 2 weeks. Daily
diaries indicated modest symptom increases during interruption with return to pre-interruption levels or better after
resumption. Interruptions had no impact on long-term efficacy outcomes.
Conclusions: Consistent with its pharmacologic properties, brief interruptions of baricitinib during phase 3 studies
were associated with minor increases in RA symptoms that resolved following retreatment. This analysis provides
useful information for clinicians, as temporary interruption of antirheumatic therapy is common in the care of
patients with RA.
Trial registration: ClinicalTrials.gov; NCT01710358, NCT01711359, NCT01721057, NCT01721044
Keywords: Rheumatoid arthritis, DMARDs (biologics), JAK inhibitors, Drug interruption
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: P.Emery@leeds.ac.uk
1Leeds Muscoloskeletal Biomedical Research Centre/Chapel Allerton Hospital,
Chapeltown Rd, Leeds LS7 4SA, UK
Full list of author information is available at the end of the article
Emery et al. Arthritis Research & Therapy          (2020) 22:115 
https://doi.org/10.1186/s13075-020-02199-8
Background
Temporary interruption of rheumatoid arthritis (RA)
therapy is common in clinical practice for various rea-
sons including side effects, non-compliance, or necessity
for surgery. Short half-life and low immunogenicity may
therefore be useful attributes for disease-modifying anti-
rheumatic drugs (DMARDs). Few studies examine what
happens when DMARDs are temporarily interrupted
and then restarted despite concerns of symptoms wors-
ening or immunogenicity increasing after the stoppage.
If disease activity deteriorates, there is also the question
of whether it will improve once the drug is started again.
Baricitinib is an oral, selective inhibitor of Janus kinase
(JAK)1 and JAK2, which belong to a family of protein
tyrosine kinases that mediate signal transduction for a
variety of cytokines involved in inflammatory conditions,
including RA [1, 2]. As a small molecule with a short
half-life (approximately 12 h in RA patients) [3], bariciti-
nib may offer advantages over injectable biologic therap-
ies with respect to ease and speed of withdrawal and re-
initiation.
Baricitinib improved signs and symptoms of RA in 4
phase 3, placebo- and active-controlled studies in patients
with active RA who were naïve to conventional synthetic
disease-modifying antirheumatic drugs (csDMARDs) (RA-
BEGIN) [4] or had an inadequate response to previous
treatment with methotrexate (MTX) (RA-BEAM) [5],
csDMARDs (RA-BUILD) [6], or biologic DMARDs (RA-
BEACON) [7]. The objectives of this analysis were to
characterize temporary interruptions of baricitinib (and
the placebo tablets in the active comparator arms) during
these studies and examine the impact of interruptions and
drug retreatment on efficacy and safety outcomes.
Methods
Study design and patients
Data were included from 4 phase 3 randomized clinical
studies. The study design and patient inclusion/exclusion
criteria for each study have been described previously [4–
7]. Briefly, 684 patients in RA-BUILD (NCT01721057)
and 527 patients in RA-BEACON (NCT01721044) with
active RA were randomized 1:1:1 to receive placebo or 2-
or 4-mg baricitinib once daily (QD); 1305 patients in RA-
BEAM (NCT01710358) were randomized 3:3:2 to receive
placebo QD or 4-mg baricitinib QD or a subcutaneous in-
jection of adalimumab every 2 weeks; and 588 patients in
RA-BEGIN (NCT01711359) were randomized 4:3:4 to re-
ceive oral MTX every week (QW) or 4-mg baricitinib QD
or 4-mg baricitinib QD plus MTX QW. Beginning at week
16 (week 24 in RA-BEGIN) in each of the studies, non-
responders, defined as patients with a lack of improve-
ment of at least 20% in both tender joint count and swol-
len joint count compared to baseline, received rescue
treatment as outlined in Additional file 1: Table S1. All
patients completing these 4 phase 3 studies were eligible
to enter the long-term extension study, RA-BEYOND.
Patients who were not receiving glucocorticoids prior
to randomization were not permitted to initiate gluco-
corticoid therapy during the study, including intra-
muscular or intra-articular glucocorticoids. After rescue,
new glucocorticoids or increases in doses of ongoing
concomitant glucocorticoids were permitted. Topical, in-
tranasal, intra-ocular, and inhaled glucocorticoids were
permitted.
The primary endpoint in the studies was the American
College of Rheumatology 20% (ACR20) response rate at
week 12 (week 24 in RA-BEGIN). In RA-BEAM and RA-
BUILD (the two studies in which patients had an inad-
equate response to csDMARDs), patients recorded daily
symptoms in an electronic diary from the first day of
treatment through week 12, referred to as diary patient-
reported outcomes (PROs). Diary entries included dur-
ation of morning joint stiffness (MJS) and numeric rat-
ing scales (NRS) for MJS severity, worst tiredness, and
worst joint pain. Scores for the NRS ranged from 0 to
10, with 10 being the worst level [8]. Additional details
regarding the study designs can be found in Additional
file 1: Table S1.
Each study was conducted in accordance with the
principles of the Declaration of Helsinki and Good Clin-
ical Practice Guidelines and approved by each center’s
institutional review board or ethics committee. All pa-
tients provided written informed consent. The studies
were designed by the sponsors, Eli Lilly and Company
and Incyte Corporation, with input from an academic
advisory board in which non-Lilly authors of this manu-
script participated. All authors participated in the prep-
aration and review of this manuscript and approved the
final version.
Characteristics of interruptions
During each study, temporary interruptions of study
drug initiated by the investigators were required to be
documented in an electronic case report form, providing
the time of the last dose, the reason for the interruption,
and the duration of the interruption. On the form, inves-
tigators could choose one of 4 reasons for the interrup-
tion: “adverse event (AE),” “abnormal laboratory values,”
“suspected pregnancy,” or “investigator decision.” If in-
vestigators selected “AE” as the reason for the interrup-
tion, they were immediately prompted to link a specific
AE to the interruption in the electronic case report
form. Investigators might have listed an abnormal
laboratory value as an “AE,” rather than selecting the
separate option of “abnormal laboratory value” as the
reason for the interruption. In these instances, we
reviewed the abnormal laboratory values individually to
gain a more complete understanding of laboratory
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abnormalities that led to interruptions. If “abnormal la-
boratory value” was selected as the reason for interrup-
tion, a query was sent to the investigator for specific
information regarding the type of laboratory test and ab-
normal finding.
Temporary interruption was defined as a temporary
withholding of study drug that was followed by the re-
sumption of study drug at a later time point. Interrup-
tions were based on the daily tablet baricitinib study
drug, including non-baricitinib groups, which repre-
sented interruptions of the matching placebo for bariciti-
nib. In some instances, the study drug was interrupted
with the intent of restarting, but instead led to a per-
manent discontinuation of treatment, which will be re-
ferred to as “initiated interruptions.” Patients who had
their daily tablet of baricitinib or matching baricitinib
placebo temporarily interrupted were compared across
their originally assigned treatment groups for trends in
the frequency, duration, and reason for baricitinib inter-
ruptions within each study. For interruptions among all
baricitinib-treated patients, including those who were
originally randomized to placebo or active-control, but
were rescued or switched to baricitinib during the stud-
ies, we provide a detailed summary of the reasons for
the interruptions.
Impact of interruptions on efficacy
Post hoc analyses to assess the impact of interruptions
on efficacy outcomes in the short- and long-term were
conducted in patients who were csDMARD-inadequate
responders (IR) and MTX-IR using pooled data of patients
randomized to placebo and baricitinib in RA-BEAM and
RA-BUILD. First, the effect on longer-term efficacy out-
comes was assessed by the percentage of patients with
ACR20 and ACR50 response and with Disease Activity
Score using 28 joints based on C-reactive protein
(DAS28-CRP) ≤ 3.2 at week 24. Responses were compared
between patients with and without interruptions of any
duration during the first 24 weeks or up to rescue.
Second, although standard RA assessments of efficacy
response and disease activity measures, with their associ-
ated acute phase reactants, were collected only at sched-
uled visits approximately every 4 weeks, the effect on
short-term efficacy outcomes was assessed through the
symptoms recorded by daily diary during the first 12
weeks of RA-BEAM and RA-BUILD. These diary scores
were examined at time landmarks in patients who were
randomized at least 7 days prior to interruption, had an
interruption that lasted at least 3 days, and were then
retreated with study drug. Symptoms were evaluated at
the following milestones:
1. Study drug initiation (average of values obtained
within the first 3 days following randomization)
2. Pre-interruption (average of up to 3 most recent
values obtained in the 7 days prior to interruption)
3. Last scores during the interruption (average of 3 most
recent values during the last 7 days of the interruption)
4. Post-interruption (average of last 3 available values
obtained following interruption and prior to any
subsequent interruption or week 12 study visit).
These 4-point profiles were compared between pa-
tients treated with and interrupting baricitinib (2 mg
and 4 mg doses combined) and patients treated with and
interrupting matching placebo.
To further explore the short-term loss of response and
increase of symptoms during interruptions, an additional
analysis was conducted of the 4 daily diary measures for
the first temporary interruption per patient during the
first 12 weeks when these measures were collected. For
each measure, patients were classified into 1 of the fol-
lowing categories:
1. Patients who reported no worsening (possibly even
improvement) of symptoms during the interruption.
2. Patients who reported only minimal worsening of
symptoms during the interruption, defined as an
increase of < 3 units of the NRS or ≤ 30 min of MJS
duration. An increase of < 3 units in the NRS was
chosen as representative of a change within severity
category based on prior use of 3- to 4-point spans
between severity categories of mild (0–3), moderate
(4–6), and severe (7–10) for MJS [9]. An increase of
30min of MJS duration was chosen as representative
of a change within severity category based on prior
use of 30-min spans between severity categories of
mild (1–30min), moderate (31–60min), and severe
(> 60min) [10].
3. Patients who temporarily reported greater than
minimal worsening of symptoms during the
interruption, defined as an increase of 3+ units of the
NRS or 31+ minutes of MJS duration, but whose last
reported symptom scores during the interruption were
improvements, not worsening, or minimal worsening.
4. Patients who reported greater than minimal
worsening of symptoms during the interruption
that did not resolve prior to resumption of
treatment. For patients in this last category, the
time for their symptoms to increase beyond
minimal worsening was categorized as occurring
during the first week, during the second week, or
beyond the second week of the interruption. For
MJS duration, these timings were considered for the
first increase of symptoms by ≥ 61 min.
Because the numbers of patients for each of these effi-
cacy assessments varied depending on efficacy and daily
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diary data available, the flow chart in Additional file 2:
Table S2 outlines and explains the sample sizes for each
assessment.
Impact of interruptions on safety
Patient-level data were assessed to provide details on
AEs and specific laboratory values that led to temporary
interruptions. Reoccurrences of AEs and laboratory find-
ings that led to a subsequent interruption after study
drug was resumed were assessed via examination of
patient-level data. For reoccurrence of AEs, matching
preferred terms using the Medical Dictionary for Regula-
tory Activities (MedDRA) with a date subsequent to the
date of drug resumption were identified in the database.
For abnormal laboratory findings, a manual review of
investigator-specified laboratory values was conducted to
determine if abnormalities with these same analytes re-
occurred once baricitinib was resumed. For a reoccur-
rence of the abnormal laboratory value to be considered,
it had to be at least as high (or low) as the value that led
to the initial interruption.
To assess whether initial tolerability effects persisted
upon reinitiation of baricitinib, AEs reported during the
first 4 weeks of treatment with baricitinib, from pooled
data across all 4 studies, were compared to AEs reported
in the 4 weeks after resuming baricitinib following a
temporary interruption for the purpose of exploring
whether the frequency and nature of the AEs were
similar.
Statistical analyses
Descriptive statistics are presented for the overall sum-
mary of interruptions, including reasons for and dur-
ation of interruptions and for efficacy and safety effects
related to interruptions. No formal hypothesis tests were
conducted to compare randomized treatment groups in
terms of the number or nature of interruptions nor to
compare specified groups with respect to the exploratory
post hoc short-term and long-term efficacy analyses.
Results
Characteristics of interruptions
Temporary interruptions of baricitinib or matching pla-
cebo occurred in 8.5 to 18.1% of patients across treat-
ment groups through week 24 and in up to 22.3%
through week 52 (Table 1). During the 4 studies, there
were 640 initiated interruptions of baricitinib or match-
ing placebo across all treatment groups; in 84% of these
cases (n = 536, range of 76–92%), the patient was able to
restart study drug, thus defining these as temporary in-
terruptions (Table 1). For patients on baricitinib during
the placebo-controlled period of the studies (or the
MTX-controlled period in RA-BEGIN), there were 343
initiated interruptions with 290 (85%) leading to
reinitiation of baricitinib. In 2 of the 3 placebo-
controlled studies (RA-BEAM and RA-BUILD), similar
proportions of patients treated with placebo (11.1% and
12.7% in RA-BEAM and RA-BUILD, respectively) and 4-
mg baricitinib (10.3% and 15.0%, in RA-BEAM and RA-
BUILD, respectively) had interruptions, while the propor-
tion of patients treated with 2-mg baricitinib (9.2%) in
RA-BUILD with an interruption was slightly lower than
the other two treatment groups. In RA-BEACON, there
was a higher proportion of patients with interruptions
with 4-mg baricitinib (18.1%) and 2-mg baricitinib (17.8%)
than with placebo (8.5%) (Table 1). In the MTX active
comparator-controlled study (RA-BEGIN), the proportion
of patients with interruptions of baricitinib or matching
placebo was lowest in the 4-mg baricitinib treatment
group (Table 1). The time from the first dose of study
treatment to interruption was longer in RA-BEGIN than
in the other studies. In RA-BEAM, the duration of inter-
ruptions of baricitinib and placebo-matched tablets was
shorter for the baricitinib treatment group compared to
the adalimumab treatment group (Table 1, Fig. 1),
although no inferential testing was performed.
The most common reason selected in the electronic
case report forms by the investigators for temporary
interruption was AE (Table 1), and the interruptions
generally lasted 2 weeks or less (Fig. 1). Overall, a small
proportion of interruptions (10.1%) where the reason
chosen was AE were further reported by the investigator
with an AE term related to an abnormal laboratory value
and were thus not included in the overall count of the
reason “abnormal laboratory result” but were counted in
the reason “adverse event” (Table 1). There were no in-
terruptions due to suspected pregnancies and few due to
investigator decision. In all baricitinib-treated patients at
any time including subsequent rescue, the most com-
mon AE leading to the interruption was infection and
most of these were respiratory infections (Table 2) that
were non-serious, and mild or moderate in severity.
Impact of interruptions on efficacy
Signs and symptoms
Patients who were csDMARD-IR (in RA-BEAM and
RA-BUILD) and experienced interruptions had similar
overall treatment responses as patients who never
interrupted, as measured by ACR20, ACR50, and
DAS28-CRP ≤ 3.2 at week 24 (Fig. 2). In these same
studies in baricitinib-treated patients, daily diary mea-
sures of severity of MJS, worst joint pain, and worst
tiredness showed modest increases during interruption
(Fig. 3). There was no increase in duration of MJS. A
similar pattern was observed in patients treated with
placebo except for worst tiredness, which did not
change during the interruption. Importantly, after re-
sumption of study drug, responses measured with the
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daily diary returned to pre-interruption levels or bet-
ter (Fig. 3). Patients with interruptions who were ran-
domized to baricitinib (having an actual change to
their treatment) had similar profiles of changes during
and following interruption as patients randomized to
placebo (having no actual change to their treatment).
Time to loss of disease control/increase in symptoms
Based on the response categories for the increase of
symptoms during the interruption, 38 to 46% of patients
reported no increases in their PRO symptoms from the
daily diaries in RA-BEAM and RA-BUILD (Add-
itional file 2: Table S2). The majority of baricitinib-
treated patients (> 59% for MJS duration and 86 to 90%
for MJS severity, worst tiredness, and worst joint pain)
reported at most minimal changes (increase of ≤ 30min
for MJS duration, increase of ≤ 2 units for other PROs)
in their daily PRO symptoms during the interruption.
Approximately 6 to 9% of baricitinib-treated patients
(except for 25% of patients for MJS duration) reported
transitory larger increases in their symptoms (≥ 31min
for MJS duration, ≥ 3 units for other PROs) that became
at most minimal increases at the time of last observa-
tion. For MJS severity and worst pain and tiredness, few
baricitinib-treated patients (3 to 9%) reported more than
minimal increases (≥ 3 units) in their symptoms that
remained increased at the last observation during the
interruption; slightly more (16%) experienced an in-
crease of > 60 min in MJS duration (Additional file 2:
Table S2). Among this last set of patients, such increases
often occurred within the first week of the interruption.
Based on these summaries, the most frequent greater-
than-minimal increase in symptoms during interruptions
was an increase in duration of MJS, followed by an in-
crease in the worst tiredness, with infrequent greater-
than-minimal increases in worst joint pain and severity
of MJS. These increases in symptoms while interrupting
baricitinib were similar among patients who interrupted
placebo.
Impact of interruptions on safety
Temporary interruptions due to AEs and reoccurrence after
resumption
Adverse events were reported as the reason for 361 tem-
porary interruptions while patients were taking bariciti-
nib (Table 2). Of these interruptions, the same AE
reoccurred in 32 cases (9%), after a mean of 58.4 days
between reinitiation of study drug and the start of the
reoccurring AE (range: 1 to 198 days). Twelve (38%) of
these reoccurrences of AEs led to another temporary
interruption in study drug and 4 (13%) led to permanent
discontinuation. The most common reoccurring AEs
were infections (n = 20, 6%).
Fig. 1 Duration of interruptions in the phase 3 studies RA-BEGIN (a), RA-BEAM (b), RA-BUILD (c), and RA-BEACON (d)a,b. aInterruptions are based
on daily tablet baricitinib study drug, including in non-baricitinib groups, which represent interruptions of the matching placebo for baricitinib.
bTemporary interruption is defined as a temporary withholding of study drug that is followed by resumption of study drug during the study.
cPercentage of interruptions. MTX, methotrexate
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Temporary interruptions due to laboratory abnormalities
and reoccurrence after resumption
Abnormal laboratory results were reported as the reason
for 37 temporary interruptions while patients were tak-
ing baricitinib (Table 2). Of the patients reporting these
interruptions, 4 had a reoccurrence of a laboratory ab-
normality that occurred 38, 40, 53, and 141 days after
reinitiation of study drug. None of the 4 reoccurrences
led to another temporary interruption or were associated
with any AEs of interest. One patient had neutrophil
count equal to 0.56 × 109 cells/L, leading to permanent
discontinuation from the study.
Tolerability
In patients who experienced interruption of baricitinib
during these studies, the most frequent AEs that oc-
curred during the first 4 weeks on treatment included
upper respiratory tract infection (URTI) (4.7% of pa-
tients who experienced an interruption), headache
(4.1%), blood creatine phosphokinase (CPK) increased
(3.1%), diarrhea (2.8%), nausea (2.5%), and bronchitis
(2.5%) (Table 3). The frequencies of these same AEs in
the first 4 weeks after baricitinib reinitiation following
interruption were 1.6% (URTI), 0.6% (headache), 0.3%
(CPK increased), 0.3% (diarrhea), 0.6% (nausea), and
0.9% (bronchitis) (Table 3). There were no specific AEs
by MedDRA preferred term with a rate of occurrence
after reinitiation that exceeded the rate during initial
treatment by > 1%.
Discussion
Treatment of patients with rheumatoid arthritis requires
long-term therapy that, at times, may need to be tem-
porarily stopped. Despite this common clinical practice,
there are little data about the efficacy response during
treatment interruptions or safety outcomes. We attempted
to characterize the rates of interruptions and the reasons
patients temporarily discontinued study drug and to
Table 2 Detailed summary of reasons for interruptions of baricitinib in the phase 3 studies, with data from all patients receiving
baricitinib at any time, including any subsequent rescue
RA-BEGIN (weeks 0–52) RA-BEAM (weeks 0–52) RA-BUILD (weeks 0–24) RA-BEACON (weeks 0–24)
All baricitinib
exposures
(N = 400)
All baricitinib
exposures
(N = 972)
All baricitinib
exposures
(N = 511)
All baricitinib
exposures
(N = 407)
Total number of interruptionsa 79 172 69 91
Reason for dose interruptionb
Adverse event 69 159 55 78
Infections (% total AEs) 39 (56.5) 93 (58.5) 36 (65.5) 55 (70.5)
Respiratory infections, n
(% of infections)
26 (66.7) 60 (64.5) 18 (50.0) 38 (69.1)
Investigations (% of total AEs)c 6 (8.7) 3 (1.9) 1 (1.8) 1 (1.3)
Abnormal laboratory resultd 9 8 12 8
Hepatic 5 1 3 1
eGFR/renal 1 1 2 2
Hemoglobin/hematocrit 3 2 0 0
Lymphocytes 0 2 1 2
Neutrophils 0 2 3 0
Creatine phosphokinase 0 0 2 2
Enrollment issue 0 0 1 1
Eosinophils 1 0 0 0
Myelocytes 0 0 1 0
Platelets 1 0 0 0
Patients who received any baricitinib dose includes patients who switched from placebo, adalimumab, or methotrexate to baricitinib, in addition to patients
randomized to any baricitinib dose. Thus, these groups will be larger than the individual baricitinib treatment groups from each study added together
aTemporary interruption is defined as a temporary withholding of study drug that is followed by resumption of study drug during the study; total count includes
interruptions occurring while assigned to any dose of baricitinib, either by initial randomization or after rescue from other treatments
bReasons for interruption were examined for baricitinib-treated patients only, including patients randomized to placebo or active-control who were rescued or
switched to baricitinib; Interruptions are based on daily tablet baricitinib study drug
cInvestigations included clinical laboratory tests (including biopsies), radiologic tests, physical examination parameters, or physiologic tests (e.g., pulmonary
function test); these included only investigation procedures and qualitative results and not conditions
dReasons for an individual interruption could be associated with multiple abnormal laboratory results
AE, adverse event; eGFR, estimated glomerular filtration rate
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Fig. 2 Percentage of 24-week responders among csDMARD/MTX-IR patients with/without interruption during the first 24 weeks. ACR20/50, 20%/
50% improvement in American College of Rheumatology criteria; csDMARD, conventional synthetic disease-modifying antirheumatic drug;
DAS28-hsCRP, Disease Activity Score based on a 28-joint count and high-sensitivity C-reactive protein; IR, inadequate responder; MTX, methotrexate
Fig. 3 Time profile of daily diary scores among csDMARD/MTX-IR patients who were retreated following interruptionsa. Data presented are
combined from RA-BEAM and RA-BUILD for duration of morning joint stiffness (a) morning joint stiffness severity (b), worst joint pain (c), and
worst tiredness (d); electronic diary data were gathered daily from week 0 to 12. aExcludes interruptions without at least 3 diary entries during
interruption. bAverage of values obtained within the first 3 days following randomization. cAverage of up to 3 most recent values obtained in the
7 days prior to interruption. dAverage of 3 most recent values in the last 7 days of the interruption. eAverage of last 3 available values obtained
following interruption and prior to any subsequent interruption or week 12 study visit. N, number of interruptions with complete time profile;
NRS, numeric rating scale
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examine the effect of those interruptions on efficacy and
safety outcomes.
During the baricitinib phase 3 trials, interruptions
were infrequent and generally of short duration (≤ 2
weeks). In RA-BEAM, the duration of the interruptions
was shorter for baricitinib (11.4 to 15.1 days) versus ada-
limumab (19.4 to 23.1 days). While the interruptions be-
ing summarized in this analysis are those for the oral
tablets (baricitinib and placebo), the longer duration of
interruptions for adalimumab could be due to the fact
that baricitinib is administered daily and orally while
adalimumab is an injection administered every 2 weeks,
and if the tablets were interrupted in conjunction with a
reason related to adalimumab, assessment to resume
study drug might have been evaluated at longer intervals.
In most studies, the interruptions occurred within the
first 2 months after the first dose of study drug. The ex-
ception was in RA-BEGIN, where patients were MTX-
naïve upon study entry and the average time to the first
interruption after study drug initiation was approxi-
mately 4 to 5 months.
Interruptions were associated with minor increases in
select RA symptoms in both the placebo and baricitinib
groups, which resolved following resumption of therapy.
The similarity between the response to withdrawal of
placebo and active drug and the similarity of the im-
provement after resumption of the respective therapies
suggests a nocebo effect [11] which was, however, rela-
tively slight. Of note, no significant loss of response was
apparent during these interruptions presumably because
of their short-term nature. Similar results were seen with
tofacitinib in patients who temporarily discontinued
tofacitinib for 14 to 30 days. These patients had similar
efficacy responses before and after interruption of the
drug [12]. These data suggest that the recurrence of
symptoms takes much longer than might be implied by
the short half-life of the JAK inhibitors.
Unlike the assessment of RA symptoms during the
interruption, we did not specifically assess the time
taken for abnormal laboratory values to return to nor-
mal. The presumption was made that the investigator
would not resume treatment if the values had not nor-
malized (or increased/decreased enough during the
interruption to remove the initial concern that caused
the interruption). Additionally, the protocols for the
studies had specific stopping and starting criteria regard-
ing laboratory abnormalities. Therefore, the average dur-
ation for the interruptions could be used as a surrogate
for the time for laboratory abnormalities to return to
normal.
Adverse events leading to interruption generally did
not reoccur upon reinitiation of treatment and, in those
that did, few led to another interruption or permanent
discontinuation. Adverse events that were observed in
the first month of treatment with baricitinib tended to
be observed less frequently upon retreatment, indicating
that tolerability effects are likely to be short-term in na-
ture and not an impediment to successful treatment
with baricitinib in the long-term or when restarting
treatment.
Conclusion
Consistent with its pharmacologic properties, temporary
interruption of baricitinib during phase 3 studies was
not followed by significant reactivation of disease and
baricitinib was rarely interrupted again after an initial
interruption. The present study should serve to provide
useful information for clinicians, as temporary interrup-
tion of antirheumatic therapy is common in the care of
patients with RA.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13075-020-02199-8.
Additional file 1: Table S1. Key study design features including patient
population. Bari, baricitinib; bDMARD, biologic disease-modifying anti-
rheumatic drugs; csDMARD, conventional synthetic disease-modifying an-
tirheumatic drugs; IR, inadequate responder; MTX, methotrexate; SC, sub-
cutaneous; TNFi, tumor necrosis factor inhibitor.
Additional file 2: Table S2. Flow chart of interruptions summarized in
efficacy analyses of RA-BEAM and RA-BUILD.
Additional file 3: Table S3. Nature and timing of increase in
symptoms/disease activity during temporary interruptions of baricitinib or
matching placebo tablets. NRS, numeric rating scale.
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ACR20: American College of Rheumatology 20% response rate; AE: Adverse
event; CPK: Creatine phosphokinase; DAS28-CRP: Disease Activity Score using
28 joints based on C-reactive protein; IR: Inadequate responder;
Table 3 Tolerability of baricitinib before and after temporary
interruption based on adverse event terms reported by ≥ 2% of
patients
n (%) First 4 weeks after
initiating baricitinib
(N = 318)
First 4 weeks after
restarting baricitinib
(N = 318)
Patients with ≥ 1 TEAE 160 (50.3) 80 (25.2)
Upper respiratory tract
infection
15 (4.7) 5 (1.6)
Headache 13 (4.1) 2 (0.6)
Blood creatine
phosphokinase increased
10 (3.1) 1 (0.3)
Diarrhea 9 (2.8) 1 (0.3)
Bronchitis 8 (2.5) 3 (0.9)
Nausea 8 (2.5) 2 (0.6)
Constipation 7 (2.2) 0
Gastroenteritis 7 (2.2) 0
Urinary tract infection 7 (2.2) 1 (0.3)
TEAE treatment-emergent adverse event
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MedDRA: Medical Dictionary for Regulatory Activities; MJS: Morning joint
stiffness; NRS: Numeric rating scale; PRO: Patient-reported outcomes;
RA: Rheumatoid arthritis; DMARD: Disease-modifying antirheumatic drugs;
JAK: Janus kinase; csDMARD: Conventional synthetic disease-modifying anti-
rheumatic drugs; MTX: Methotrexate; QD: Once daily; QW: Every week
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